These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 21172575)

  • 1. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
    Caroff SN; Hurford I; Lybrand J; Campbell EC
    Neurol Clin; 2011 Feb; 29(1):127-48, viii. PubMed ID: 21172575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
    Barnes TR; McPhillips MA
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
    Yoshida K; Bies RR; Suzuki T; Remington G; Pollock BG; Mizuno Y; Mimura M; Uchida H
    Schizophr Res; 2014 Mar; 153(1-3):184-8. PubMed ID: 24491908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapy.
    Buckley PF
    J Clin Psychiatry; 2008 May; 69(5):e14. PubMed ID: 18681759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients.
    Janno S; Holi M; Tuisku K; Wahlbeck K
    Am J Psychiatry; 2004 Jan; 161(1):160-3. PubMed ID: 14702266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
    Dold M; Samara MT; Li C; Tardy M; Leucht S
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice.
    Caroff SN; Campbell EC
    Psychiatr Clin North Am; 2016 Sep; 39(3):391-411. PubMed ID: 27514296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study.
    Ryu S; Yoo JH; Kim JH; Choi JS; Baek JH; Ha K; Kwon JS; Hong KS
    J Clin Psychopharmacol; 2015 Feb; 35(1):13-21. PubMed ID: 25485636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
    McCreadie RG; Robertson LJ; Wiles DH
    Br J Psychiatry; 1992 Jun; 160():793-9. PubMed ID: 1352165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of the CATIE trial on treatment: extrapyramidal symptoms.
    Casey DE
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):25-31. PubMed ID: 16816797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons to take home from CATIE.
    Carpenter WT; Buchanan RW
    Psychiatr Serv; 2008 May; 59(5):523-5. PubMed ID: 18451009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients.
    Parksepp M; Ljubajev Ü; Täht K; Janno S
    Nord J Psychiatry; 2016 Oct; 70(7):498-502. PubMed ID: 27093226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.
    Lieberman JA
    J Clin Psychiatry; 2007 Feb; 68(2):e04. PubMed ID: 17335312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
    Schulz C; Timm J; Cordes J; Gründer G; Mühlbauer B; Rüther E; Heinze M
    Clin Trials; 2016 Jun; 13(3):251-9. PubMed ID: 27016729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perphenazine suspension: a new, old treatment, side effects and continuous use.
    Chrisphonte P; Ostroff RB; Rosenheck RA
    Psychiatr Q; 2012 Sep; 83(3):335-41. PubMed ID: 22271354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.